303 related articles for article (PubMed ID: 21901670)
1. A status update of modified oligonucleotides for chemotherapeutics applications.
Sanghvi YS
Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany.
Uhlmann E
Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic oligonucleotides.
Goodchild J
Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
[TBL] [Abstract][Full Text] [Related]
4. Antisense and/or immunostimulatory oligonucleotide therapeutics.
Agrawal S; Kandimalla ER
Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic oligonucleotides: a review].
Wang X; Xian J; Chen G; Peng H
Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
7. Sugar boost: when ribose modifications improve oligonucleotide performance.
Faria M; Ulrich H
Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
9. Safety of antisense oligonucleotide and siRNA-based therapeutics.
Chi X; Gatti P; Papoian T
Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic oligonucleotides: the state-of-the-art in purification technologies.
Sanghvi YS; Schulte M
Curr Opin Drug Discov Devel; 2004 Nov; 7(6):765-76. PubMed ID: 15595437
[TBL] [Abstract][Full Text] [Related]
11. [Oligonucleotide therapeutics - an emerging novel class of compounds].
Wacheck V
Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
[TBL] [Abstract][Full Text] [Related]
12. RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions.
MacLeod AR; Crooke ST
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S43-S59. PubMed ID: 28921648
[TBL] [Abstract][Full Text] [Related]
13. Design and applications of modified oligonucleotides.
Gallo M; Montserrat JM; Iribarren AM
Braz J Med Biol Res; 2003 Feb; 36(2):143-51. PubMed ID: 12563516
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond.
Coppelli FM; Grandis JR
Curr Pharm Des; 2005; 11(22):2825-40. PubMed ID: 16101440
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic oligonucleotides with polyethylene glycol modifications.
Winkler J
Future Med Chem; 2015; 7(13):1721-31. PubMed ID: 26465713
[TBL] [Abstract][Full Text] [Related]
18. Progress on RNA-based therapeutics for genetic diseases.
Luo T; Huo C; Zhou T; Xie S
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 52(4):406-416. PubMed ID: 37643975
[TBL] [Abstract][Full Text] [Related]
19. Current progress on aptamer-targeted oligonucleotide therapeutics.
Dassie JP; Giangrande PH
Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
[TBL] [Abstract][Full Text] [Related]
20. Oligonucleotide delivery: a patent review (2010 - 2013).
Grijalvo S; Aviñó A; Eritja R
Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
